Erratum: A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study (Gynecol Oncol 127 (2012) (538-543))

a Dept. of Gynecologic Oncology & Reproductive Medicine, University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA b Gynecologic Oncology Group Statistical & Data Center, Roswell Park Cancer Institute, Buffalo, NY 14263, USA c Gynecologic Oncology/Clinical Trials Dept., Walter Reed National Military Medical Center — Bethesda, Bethesda, MD 20889, USA d Dept. of Obstetrics & Gynecology, Division of Gynecologic Oncology, Florida Hospital Cancer Institute, Orlando, FL 32804, USA e Dept. of Obstetrics & Gynecology, Division of Gynecologic Oncology, The Hospital of Central Connecticut, New Britain, CT 06050, USA f Dept. of Obstetrics & Gynecology, Division of Gynecologic Oncology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA g Dept. of Obstetrics & Gynecology, Division of Gynecologic Oncology, Saint Vincent's Hospital, Indianapolis, IN 46260, USA h Pacific Gynecologic Specialists, PD, Seattle, WA 98104, USA i Dept. of Obstetrics & Gynecology, Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City, OK 73190, USA j Dept. of Pathology, University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA k Department of Gynecologic Oncology, Center for RNA Interference and Non-Coding RNA, University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA l Department of Reproductive Medicine, Center for RNA Interference and Non-Coding RNA, University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA m Department of Cancer Biology, Center for RNA Interference and Non-Coding RNA, University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA n Dept. of Pathology, The University of Kansas Medical Center, Kansas City, KS 66160, USA o Protocol Support Laboratory, Fox Chase Cancer Center, Philadelphia, PA 19111, USA